Evidence map›Paper›PMID 35371700›Full record

ArticleCureus2022

Generalized Papulovesicular Eruption as a Side Effect of the Pfizer-BioNTech COVID-19 Vaccine.

Awadh Alamri, Yara Alghamdi, Safa J Alamri, Malak K Althaqafi, Wasan AlQurashi, Bader A Bader, Abdulrahman T Mohanna, Bashaer Almahdi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Awadh AlamriDermatology, King Abdulaziz Medical City, Jeddah, SAU.
Yara AlghamdiCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Safa J AlamriDermatology, King Abdullah International Medical Research Center, Jeddah, SAU.
Malak K AlthaqafiGeneral Practice, King Abdulaziz Hospital, Ministry of Health, Makkah, SAU.
Wasan AlQurashiDermatology, King Abdulaziz University Hospital, Jeddah, SAU.
Bader A BaderDermatology, King Abdulaziz Medical City, Jeddah, SAU.
Abdulrahman T MohannaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Bashaer AlmahdiCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
King Abdullah International Medical Research Center · SAKing Saud bin Abdulaziz University for Health Sciences · SAKing Abdulaziz Hospital · SAKing Abdulaziz Medical City · SAKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is inflicted by SARS-CoV-2 and resulted in a global health crisis that necessitated the urgency of vaccine development to prevent its spreading among the public. Pfizer-BioNTech COVID-19 is one of the emergency use authorized (EUA) vaccines. This vaccine is efficacious against the SARS-CoV-2 virus; nonetheless, recipients have frequently reported side effects. Recipients of this vaccine experienced miscellaneous side effects like fatigue and headache. However, cutaneous eruptions of varying degrees of severity and involvements have been manifesting post-vaccination. Dermatological eruptions following vaccination against COVID-19 disease are poorly recognized. Dermatological manifestations triggered post-vaccination differ in the clinical context and patient's demographic features. The only constant factor is various clinical and histopathological relations to establish the diagnosis of cutaneous eruption post-vaccination. Herein, we report a case of an 18-year-old male with T-cell acute lymphocytic lymphoma (ALL) in remission since August 2018 and other comorbidities. After the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine, the patient developed pruritic eczematous eruption presenting as grouped erythematous-violaceous papulovesicular lesions with fine scales over his upper and lower extremities. These eruptions started two days after the administration of the vaccine. This eruption became generalized 21 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine. Clinical suspicion of the drug-induced vesicular eruption was suspected; thus, a biopsy was obtained and showed erosions and mixed inflammatory cell infiltrate. From a clinical and histopathological correlation, vesicular eruption following vaccination with Pfizer-BioNTech COVID-19 was confirmed. Nevertheless, other diagnoses cannot be ruled out, but from the clinical-histopathological association, the vaccine-inflicted eruption is the likely culprit. Reports are crucial to understanding the nature of such dermatological manifestation after emerging diseases and counteractions like vaccinations. The dermatological manifestations are vaguely recognized; thus, by reporting on the cases similar to the case in this report, more data will be available to understand the nature and underlying cause of such eruptions.

Indexed as

bnt162b2 mrna vaccinebnt162b2 vaccinecovid-19cutaneous eruptiondermatologypapulovesicularpapulovesicular eruptionpfizer-biontech covid-19 vaccinepfizer vaccinevaccine

Identifiers

PMID35371700
PMCPMC8941327
OpenAlexW4213201647

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.